Entity family
Named medicines, compounds, vaccines, and pharmacological agents. Examples include metformin, semaglutide, antibiotics.
This drug is selected. Its supporting articles are shown below.
…(NIVO+RELA) to BRAF/MEK inhibitors, we compared its efficacy to dabrafenib+trametinib (DAB+TRAM), encorafenib+binimetinib (ENCO+BINI), vem…
…emotherapy, pembrolizumab-based chemoimmunotherapy (Pembro) and nivolumab plus ipilimumab with or without two cycles of platinum-doublet …
…tumor, non-tumorous liver, and peripheral blood compartments in nivolumab responders (nivo-Rs). Shared clonotypes were positively associa…
…Skin was the most common site of primary malignancy (n=67;62%). Pembrolizumab (n=44;40.7%) and Ipilimumab/Nivolumab in combination (n=44;40.7…
…ith filters for RCTs. We restricted our analysis to ipilimumab, nivolumab, pembrolizumab, atezolizumab, avelumab, durvalumab, cemiplimab …
…nclusion, the patient underwent neoadjuvant chemoimmunotherapy (nivolumab, carboplatin and paclitaxel) followed by surgery (right thoraco…
…e very limited. For decades, tyrosine kinase inhibitors such as sorafenib and lenvatinib have been the only first-line treatments for adv…
…d. Those without radiographic recurrence (RECIST v1.1) received iNeo-Vac-P01 (300 μg/peptide + GM-CSF 40 μg) subcutaneously on a multi-dose …
…hort 1 has 43 patients all with HLA A2 receiving ipilimumab and nivolumab with 10 doses of intra-muscular SCIB1 over 24-months. Cohort 3 …
…nicalTrials.gov between 2014 and 2024 evaluating approved ICIs (nivolumab, pembrolizumab, atezolizumab, durvalumab, avelumab, ipilimumab,…
…59(6371):97–103.Hellmann MD, Paz-Ares L, Bernabe Caro R, et al. Nivolumab plus ipilimumab in advanced NSCLC. N Engl J Med. 2019;381(21):2…
…, Wai ES, et al. Survival outcomes following discontinuation of ipilimumab and nivolumab for advanced melanoma in a population-based cohor…